Måndag 22 December | 13:11:10 Europe / Stockholm

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2025-12-22 09:29:00

As we look ahead to 2026, SynAct Pharma is summing up a year marked by a broadened pipeline, increased ambitions and a strengthened financial position. In an interview with BioStock, CEO Jeppe Øvlesen and CBO Mads Bjerregaard talk about where the company stands at the end of 2025, how the pipeline and business development work is progressing, and what milestones and opportunities may characterise the coming year.

See the interview biostock.se:
SynAct Pharma: "2026 is going to be a busy year"
 
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/